467 related articles for article (PubMed ID: 15235215)
1. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.
Dhindsa G; Bhatia R; Dhindsa M; Bhatia V
J Postgrad Med; 2004; 50(2):140-4. PubMed ID: 15235215
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance in polycystic ovarian disease.
Bhatia V
South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
[TBL] [Abstract][Full Text] [Related]
3. Insulin resistance and metformin in polycystic ovary syndrome.
Ben-Haroush A; Yogev Y; Fisch B
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):125-33. PubMed ID: 15262344
[TBL] [Abstract][Full Text] [Related]
4. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
Sharma ST; Nestler JE
Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
[TBL] [Abstract][Full Text] [Related]
5. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
6. Metformin in polycystic ovary syndrome.
Diamanti-Kandarakis E; Economou F; Palimeri S; Christakou C
Ann N Y Acad Sci; 2010 Sep; 1205():192-8. PubMed ID: 20840272
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
8. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D
Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and polycystic ovary syndrome.
Galluzzo A; Amato MC; Giordano C
Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):511-8. PubMed ID: 18657405
[TBL] [Abstract][Full Text] [Related]
10. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
Tan BK; Adya R; Chen J; Farhatullah S; Heutling D; Mitchell D; Lehnert H; Randeva HS
Cardiovasc Res; 2009 Aug; 83(3):566-74. PubMed ID: 19414528
[TBL] [Abstract][Full Text] [Related]
11. Use of metformin in polycystic ovary syndrome.
Mathur R; Alexander CJ; Yano J; Trivax B; Azziz R
Am J Obstet Gynecol; 2008 Dec; 199(6):596-609. PubMed ID: 19084097
[TBL] [Abstract][Full Text] [Related]
12. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
13. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
[TBL] [Abstract][Full Text] [Related]
14. Use of insulin sensitizers in polycystic ovarian syndrome.
Baillargeon JP
Curr Opin Investig Drugs; 2005 Oct; 6(10):1012-22. PubMed ID: 16259222
[TBL] [Abstract][Full Text] [Related]
15. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Svendsen PF; Nilas L; Nørgaard K; Madsbad S
Ugeskr Laeger; 2005 Aug; 167(34):3147-51. PubMed ID: 16117910
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome: evolution of a concept.
Ruutiainen K; Seppälä M
Curr Opin Obstet Gynecol; 1991 Jun; 3(3):326-35. PubMed ID: 1813001
[TBL] [Abstract][Full Text] [Related]
17. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome.
Checa MA; Requena A; Salvador C; Tur R; Callejo J; Espinós JJ; Fábregues F; Herrero J;
Hum Reprod Update; 2005; 11(4):375-90. PubMed ID: 15878899
[TBL] [Abstract][Full Text] [Related]
18. When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Franks S
Clin Endocrinol (Oxf); 2011 Feb; 74(2):148-51. PubMed ID: 21121941
[TBL] [Abstract][Full Text] [Related]
19. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.
Pasquali R; Gambineri A
Expert Opin Ther Targets; 2009 Oct; 13(10):1205-26. PubMed ID: 19650762
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
